Dr. Allibert holds a PhD in molecular biology for the University of Grenoble, France, and has more than 25 years of experience within the molecular diagnostic and vaccine industry. He has acted as an expert for the European Community and is now a member of the board of the Institute of Infection and Immunity of the Canadian Institute of Health Research (CIHR). From 2006 to 2012, Dr. Allibert was the Vice-president R&D and Vice-president of molecular innovation at Becton Dickinson (BD) Diagnostic GeneOhm where he developed many molecular diagnostic products while overseeing the construction of BD’s fabrication centre and a research centre in the High Tech Park of Québec City. From 2001 to 2006 at Merial, Dr. Allibert was the director of bioanalytical development. He has led R&D teams in France and the USA and has launched many innovative vaccines. At bioMérieux, Dr. Allibert was a pioneer of molecular diagnostics and was responsible for the launch of the first molecular test (HLA-DR) used in bone marrow and organ transplantation.